Kiromic Biopharma

Kiromic Biopharma, Inc. operates as a clinical-stage biotherapeutics company. Its platform, DIAMOND AI, discovers, validates, and develops cell and gene therapies with a therapeutic focus on immuno-oncology. The company is in the process of developing ALEXIS, a multi-indication allogeneic CAR-T cell therapy platform that exploits the natural potency of gamma delta T-cells to target solid cancers. The company was founded by Maurizio Chiriva-Internati and Scott Dahlbeck on August 6, 2006 and is headquartered in Houston, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Kiromic Biopharma, Inc. is a clinical stage biotherapeutics company, which engages in DIAMOND AI and discovers, validates, and develops cell and gene therapies with a therapeutic focus on immuno-oncology. The firm is in the process of developing ALEXIS, a multi-indication allogeneic CAR-T cell therapy platform that exploits the natural potency of gamma delta T-cells to target solid cancers. The company was founded by Maurizio Chiriva-Internati and Scott Dahlbeck on August 6, 2006 and is headquartered in Houston, TX.

HOUSTON--(BUSINESS WIRE)-- #CART--Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage, fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immuno-oncology, announces the appointments of Pamela Misajon and Michael Catlin to its Board of Directors. Their regulatory and finance experience enhances Kiromic's governance and re-establishes the Company's five-member.

Kiromic BioPharma Welcomes Two New Directors to its Board

HOUSTON--(BUSINESS WIRE)---- $KRBP #CART--Kiromic BioPharma Announces FDA Authorization of IND to Initiate Phase 1 Clinical Trial Evaluating Deltacel in Non-Small Cell Lung Cancer.

Kiromic BioPharma Announces FDA Authorization of IND to Initiate Phase 1 Clinical Trial Evaluating Deltacel in Non-Small Cell Lung Cancer

HOUSTON--(BUSINESS WIRE)---- $KRBP #CART--Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immuno-oncology, announces the submission of an Investigational New Drug (IND) application to the U.S.

Kiromic BioPharma Submits Investigational New Drug Application for Phase 1 Trial with Deltacel for Non-Small Cell Lung Cancer

HOUSTON--(BUSINESS WIRE)-- #CART--Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immune-oncology, announces that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-30 effective as of 4:01 p.m. Eastern Time today, March 10, 2023.

Kiromic BioPharma Announces Reverse Stock Split

Adial Pharmaceuticals Inc

Akebia Therapeutics

Asensus Surgical

Borqs Technologies

Blue Star Foods Corp

Myomo

Novo Integrated Sciences, Inc.

Sono Group NV

vTv Therapeutics

Penny stocks under $1 to watch right now. The post 10 Hot Penny Stocks Under $1 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

10 Hot Penny Stocks Under $1 To Watch This Week

HOUSTON--(BUSINESS WIRE)---- $KRBP #CART--Kiromic BioPharma, Inc.

Kiromic BioPharma Reports Favorable Deltacel™ Preclinical Pharmacology Results

HOUSTON--(BUSINESS WIRE)---- $KRBP #CART--Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immuno-oncology, announces that Institutional Shareholder Services (ISS) and Glass Lewis & Co.

Two Leading Independent Proxy Advisory Firms Recommend Kiromic BioPharma Stockholders Vote “FOR” All Proxy Proposals

HOUSTON--(BUSINESS WIRE)-- #CART--Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immuno-oncology, today issued the following letter to stockholders from its CEO Pietro Bersani.

Kiromic BioPharma CEO Issues Letter to Stockholders

SAN FRANCISCO , Nov. 8, 2022 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP is investigating potential derivative claims on behalf of shareholders of Kiromic Biopharma, Inc. (NASDAQ: KRBP) relating to possible false and misleading statements to investors concerning commercial prospects for the company's immunotherapy medications.  Kiromic is a target discovery and gene-editing company which utilizes artificial intelligence to create immunotherapy products.

SHAREHOLDER ALERT: Kiromic Biopharma, Inc. (KRBP) Officers and Directors Under Investigation for Possible False Statements About Its Commercial Prospects

HOUSTON--(BUSINESS WIRE)-- #CART--Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell and gene therapies with a focus on immuno-oncology, announces it entered into a Standby Equity Purchase Agreement (the “SEPA”) with YA II PN, LTD, a partnership managed by Yorkville Advisors Global LP, a global investment manager, to sell up to $8 mi

Kiromic BioPharma Arranges Up to $10 Million Financing

HOUSTON--(BUSINESS WIRE)---- $KRBP #CART--Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell and gene therapies with a focus on immuno-oncology, announces it received validating written feedback on October 4, 2022 from the FDA pursuant to its Type B Pre-IND meeting request regarding its Deltacel™ development strategy. The purpose of the Pre-

Kiromic BioPharma Announces FDA Feedback from Type B Pre-IND Meeting Confirms Deltacel Development Strategy

San Francisco, California--(Newsfile Corp. - October 4, 2022) - Hagens Berman urges Kiromic BioPharma, Inc. (NASDAQ: KRBP) investors who purchased Kiromic shares to submit your losses now.Relevant Period: June 25, 2021 - Feb. 2, 2022Lead Plaintiff Deadline: Oct. 4, 2022Visit: https://www.hbsslaw.com/investor-fraud/KRBP Contact An Attorney Now: KRBP@hbsslaw.com 844-916-0895Kiromic BioPharma, Inc.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Kiromic BioPharma (KRBP) Investors with Losses to Lead Plaintiff Deadline in Securities Class Action

Los Angeles, California--(Newsfile Corp. - October 4, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Kiromic BioPharma, Inc. ("Kiromic" or "the Company") (NASDAQ: KRBP) for violations of the federal securities laws.

DEADLINE TODAY: The Schall Law Firm Encourages Investors in Kiromic BioPharma, Inc. with Losses of $100,000 to Contact the Firm

NEW YORK , Oct. 4, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Kiromic BioPharma, Inc. (NASDAQ: KRBP) alleging that the Company violated federal securities laws. This lawsuit is on behalf of a class consisting of persons and entities that purchased or otherwise acquired: (a) Kiromic common stock issued in connection with the Company's public offering that closed on July 2, 2021 and/or (b) Kiromic common stock between June 25, 2021 and August 13, 2021, both dates inclusive.Lead Plaintiff Deadline: October 4, 2022 No obligation or cost to you.

KRBP ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 4, 2022 in the Class Action Filed on Behalf of Kiromic BioPharma, Inc. Shareholders

LOS ANGELES, CA / ACCESSWIRE / October 3, 2022 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Kiromic BioPharma, Inc. ("Kiromic" or "the Company") (NASDAQ:KRBP) for violations of the federal securities laws. Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted on July 2, 2021 (the "IPO"), and/or between June 25, 2021 and August 13, 2021, inclusive (the ''Class Period''), are encouraged to contact the firm before October 4, 2022.

FINAL DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Kiromic BioPharma, Inc. With Losses of $75,000 to Contact the Firm

New York, New York--(Newsfile Corp. - October 3, 2022) - Levi & Korsinsky, LLP notifies investors in Kiromic BioPharma, Inc. ("Kiromic" or the "Company") (NASDAQ: KRBP) of a class action securities lawsuit.The lawsuit on behalf of Kiromic investors has been commenced in the the United States District Court for the Southern District of New York.

KRBP LAWSUIT ALERT: Levi & Korsinsky Notifies Kiromic BioPharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK , Oct. 3, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Kiromic BioPharma Inc. ("Kiromic" or the "Company") (NASDAQ: KRBP).  Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kiromic BioPharma Inc. -KRBP

New York, New York--(Newsfile Corp. - October 3, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Kiromic BioPharma, Inc.

KRBP FINAL DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Kiromic BioPharma, Inc. Investors with Losses to Secure Counsel Before Important October 4 Deadline in Securities Class Action - KRBP

Los Angeles, California--(Newsfile Corp. - October 3, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Kiromic BioPharma, Inc. ("Kiromic" or "the Company") (NASDAQ: KRBP) for violations of the federal securities laws.

DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Kiromic BioPharma, Inc. with Losses of $100,000 to Contact the Firm

NEW YORK , Oct. 3, 2022 /PRNewswire/ -- Attention Kiromic BioPharma, Inc. ("Kiromic") (NASDAQ: KRBP) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors. This lawsuit is on behalf of a class consisting of persons and entities that purchased or otherwise acquired: (a) Kiromic common stock issued in connection with the Company's public offering that closed on July 2, 2021 and/or (b) Kiromic common stock between June 25, 2021 and August 13, 2021, both dates inclusive.

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Kiromic Investors of a Lead Plaintiff Deadline of October 4, 2022

RADNOR, Pa. , Oct. 2, 2022 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kiromic BioPharma, Inc.  ("Kiromic") (NASDAQ: KRBP).

KRBP Shareholder Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Kiromic BioPharma, Inc. of Deadline in Securities Fraud Class Action Lawsuit

San Francisco, California--(Newsfile Corp. - October 1, 2022) - Hagens Berman urges Kiromic BioPharma, Inc. (NASDAQ: KRBP) investors who purchased Kiromic shares to submit your losses now. Class Period: June 25, 2021 - Aug. 13, 2021Lead Plaintiff Deadline: Oct. 4, 2022Visit: https://www.hbsslaw.com/investor-fraud/KRBPContact An Attorney Now: KRBP@hbsslaw.com844-916-0895Kiromic BioPharma, Inc. (KRBP) Securities Class Action: The litigation focuses on Kiromic's statements about its development of two cancer treatment product candidates

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Kiromic BioPharma (KRBP) Investors with Significant Losses to Contact Firm's Attorneys Before Oct. 4th Application Deadline in Securities Class Action

NEW YORK , Sept. 30, 2022 /PRNewswire/ -- WHY:Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Kiromic BioPharma, Inc. (NASDAQ: KRBP): (i) pursuant and/or traceable to the offering documents issued in connection with the Company's initial public offering conducted on or about July 2, 2021 (the "IPO"); and/or (ii) between June 25, 2021 and August 13, 2021, both dates inclusive (the "Class Period"), of the important October 4, 2022 lead plaintiff deadline.

KRBP TUESDAY DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Kiromic BioPharma, Inc. Investors With Losses to Secure Counsel Before Important October 4 Deadline in Securities Class Action - KRBP

Radnor, Pennsylvania--(Newsfile Corp. - September 30, 2022) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kiromic BioPharma, Inc. ("Kiromic") (NASDAQ: KRBP). The action charges Kiromic with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects.

KRBP DEADLINE: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Kiromic BioPharma, Inc. of Deadline in Securities Fraud Class Action Lawsuit and Encourages Investors with Substantial Losses to Contact the Firm

Los Angeles, California--(Newsfile Corp. - September 30, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Kiromic BioPharma, Inc. ("Kiromic" or "the Company") (NASDAQ: KRBP) for violations of the federal securities laws.

News for Kiromic Biopharma Stock (KRBP)